[1]Torre LA,Bray F,Siegel RL,et al.Global cancer statistics,2012［J］.Cancer J Clin,2015,65(2):87-108.
[2]Abdulrahman GO Jr,Rahman GA.Epidemiology of breast cancer in Europe and Africa［J］.J Cancer Epidemiol,2012,2012:915610.
[3]Rucci N,Sanità P,Delle Monache S,et al.Molecular pathogenesis of bone metastases in breast cancer:Proven and emerging therapeutic targets［J］.World J Clin Oncol,2014,5(3):335-347.
[4]Ren G,Esposito M,Kang Y.Bone metastasis and the metastatic niche［J］.J Mol Med（Berl),2015,93(11):1203-1212.
[5]Van der Pol CB,Schweitzer ME,Di Primio G,et al.Breast cancer and bone metastases:The association of axial skeleton MRI findings with skeletal-related events and survival［J］.Breast Cancer Res Treat,2014,146(3):583-589.
[6]Guise TA.Breast cancer bone metastases:It's all about the neighborhood［J］.Cell,2013,154(5):957-959.
[7]Boyle WJ,Simonet WS,Lacey DL.Osteoclast differentiation and activation［J］.Nature,2003,423(6937):337-342.
[8]Theriault RL,Theriault RL.Biology of bone metastases［J］.Cancer Control,2012,19(2):92-101.
[9]Roodman GD.Mechanisms of bone metastasis［J］.N Engl J Med,2004,350(16):1655-1664.
[10]Sung B,Oyajobi B,Aggarwal BB.Plumbagin inhibits osteoclastogenesis and reduces human breast cancer-induced osteolytic bone metastasis in mice through suppression of RANKL signaling［J］.Mol Cancer Ther,2012,11(2):350-359.
[11]Larson SR,Zhang X,Dumpit R,et al.Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases［J］.Prostate,2013,73(9):932-940.
[12]Paget S.The distribution of secondary growths in cancer of the breast 1889［J］.Cancer Metastasis Rev,1989,8(2):98-101.
[13]Massagué J,Obenauf AC.Metastatic colonization by circulating tumourcells［J］.Nature,2016,529(7586):298-306.
[14]Pece S,Tosoni D,Confalonieri S,et al.Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content［J］.Cell,2010,140(1):62-73.
[15]Suva LJ,Washam C,Nicholas RW,et al.Bone metastasis:Mechanisms and therapeutic opportunities［J］.Nat Rev Endocrinol,2011,7(4):208-218.
[16]Lian JB,Stein GS,Van Wijnen AJ,et al.MicroRNA control of bone formation and homeostasis［J］.Nat Rev Endocrinol,2012,8(4):212-227.
[17]Tang J,Ahmad A,Sarkar FH.The role of microRNAs in breast cancer migration,invasion and metastasis［J］.Int J Mol Sci,2012,13(10):13414-13437.
[18]Singh R,Pochampally R,Watabe K,et al.Exosome mediated transfer of miR-10b promotes cell invasion in breast cancer［J］.Mol Cancer,2014,13:256.
[19]Lukanidin E,Sleeman JP.Building the niche:The role of the S100 proteins in metastatic growth［J］.Semin Cancer Biol,2012,22(3):216-225.
[20]Li XQ,Du X,Li DM,et al.ITGBL1 is a Runx2 transcriptional target and promotes breast cancer bone metastasis by activating the TGFβ signaling pathway［J］.Cancer Res,2015,75(16):3302-3313.
[21]Hoshino A,Costa-Silva B,Shen TL,et al.Tumour exosome integrins determine organotropic metastasis［J］.Nature,2015,527(7578):329-335.
[22]Psaila B,Lyden D,Comen EA.Tracking the seed and tending the soil:Evolving concepts in metastatic breast cancer［J］.Discov Med,2012,14(75):97-104.
[23]Zhang L,Zhang S,Yao J,et al.Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth［J］.Nature,2015,527(7576):100-104.
[24]Valastyan S,Weinberg RA.Tumor metastasis:Molecular insights and evolving paradigms［J］.Cell,2011,147(2):275-292.
[25]Walker ND,Patel J,Munoz JL,et al.The bone marrow niche in support of breast cancer dormancy［J］.Cancer Lett,2015,15:00664-00673.
[26]Price TT,Burness ML,Sivan A,et al.Dormant breast cancer micrometastases reside in specific bone marrow niches that regulate their transit to and from bone［J］.Sci Transl Med,2016,8(340):340ra73.
[27]Kaplan RN,Riba RD,Zacharoulis S,et al.VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche［J］.Nature,2005,38(7069):820-827.
[28]Cox TR,Rumney RM,Schoof EM,et al.The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase［J］.Nature,2015,522(7554):106-110.
[29]Sterling JA,Edwards JR,Martin TJ,et al.Advances in the biology of bone metastasis:How the skeleton affects tumor behavior［J］.Bone,2011,48(1):6-15.
[30]Weilbaecher KN,Guise TA,McCauley LK.Cancer to bone:A fatal attraction［J］.Nat Rev Cancer,2011,11(6):411-425.
[31]Savci-Heijink CD,Halfwerk H,Koster J,et al.A novel gene expression signature for bone metastasis in breast carcinomas［J］.Breast Cancer Res Treat,2016,156(2):249-259.
[32]Kiesel L,Kohl A.Role of the RANK/RANKL pathway in breast cancer［J］.Maturitas,2016,86:10-16.
[33]Aft R,Naughton M,Trinkaus K,et al.Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer:An open label,randomised,phase 2 trial［J］.Lancet Oncol,2010,11(5):421-428.
[34]Stopeck AT,Lipton A,Body JJ,et al.Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer:A randomized,double-blind study［J］.J Clin Oncol,2010,28(35):5132-5139.
[35]Vadhan-Raj S,Von Moos R,Fallowfield LJ,et al.Clinical benefit in patients with metastatic bone disease:Results of phase 3 study of denosumab versus zoledronic acid［J］.Ann Oncol,2012,23(12):3045-3051.
[36]Jensen AB,Wynne C,Ramirez G,et al.The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases:Results of a 4-week,double-blind,randomized,controlled trial［J］.Clin Breast Cancer,2010,10(6):452-458.
[37]Rucci N,Susa M,Teti A.Inhibition of protein kinase c-Src as a therapeutic approach for cancer and bone metastases［J］.Anticancer Agents Med Chem,2008,8(3):342-349.
[38]Desgrosellier JS,Cheresh DA.Integrins in cancer:Biological implications and therapeutic opportunities［J］.Nature Rev Cancer,2010,10(1):9-22.
[39]Korpal M,Kang Y.Targeting the transforming growth factor-β signalling pathway in metastatic cancer［J］.Eur J Cancer,2010,46(7):1232-1240.
[40]Wright LE,Frye JB,Lukefahr AL,et al.Curcuminoids block TGF-β signaling in human breast cancer cells and limit osteolysis in a murine model of breast cancer bone metastasis［J］.J Nat Prod,2013,76(3):316-321.
[41]Bendinelli P,Maroni P,Matteucci E,et al.Microenvironmental stimuli affect Endothelin-1 signaling responsible for invasiveness and osteomimicry of bone metastasis from breast cancer［J］.Biochim Biophys Acta,2014,1843(4):815-826.
[42]Krzeszinski JY,Wan Y.New therapeutic targets for cancer bone metastasis［J］.Trends Pharmacol Sci,2015,36(6):360-373.
[43]Peyruchaud O,Serre CM,Nic Amhlaoibh R,et al.Angiostatin inhibits bone metastasis formation in nude mice through a direct anti-osteoclastic activity［J］.J Biol Chem,2003,278(46):45826-45832.
[44]Schroeder M,Viezens L,Wellbrock J,et al.Sunitinib treatment reduces tumor growth and limits changes in microvascular properties after minor surgical intervention in an in vivo model of secondary breast cancer growth in bone［J］.J Surg Oncol,2016,113(5):515-521.
[45]Bachelier R,Confavreux CB,Peyruchaud O,et al.Combination of anti-angiogenic therapies reduces osteolysis and tumor burden in experimental breast cancer bone metastasis［J］.Int J Cancer,2014,135(6):1319-1329.
[46]Irvin W Jr,Muss HB,Mayer DK.Symptom management in metastatic breast cancer［J］.Oncologist,2011,16(9):1203-1214.
[47]Esposito M,Kang Y.Targeting tumor-stromal interactions in bone metastasis［J］.Pharmacol Ther,2014,141(2):222-233.
[48]Coleman RE.Clinical features of metastatic bone disease and risk of skeletal morbidity［J］.Clin Cancer Res,2006,12(20 Pt 2):6243s-6249s.
[49]Chow E,Zeng L,Salvo N,et al.Update on the systematic review of palliative radiotherapy trials for bone metastases［J］.Clin Oncol（R Coll Radiol),2012,24(2):112-124.
[50]Ju DG,Yurter A,Gokaslan ZL,et al.Diagnosis and surgical management of breast cancer metastatic to the spine［J］.World J Clin Oncol,2014,5(3):263-271.
[51]De Souza N,Ward N.Magnetic resonance-guided high-intensity-focused ultrasound for the treatment of cancer-related pain［J］.Pain Manag,2015,5(4):221-224.